What the company does
Icure Pharmaceutical makes medicated skin patches, adhesive drug-delivery systems worn on the body, as well as skincare and sheet-mask products manufactured under contract for other brands.
It supplies pharmaceutical customers and cosmetics companies, and is listed on KOSDAQ, South Korea's tech and small-cap exchange. The large majority of its revenue comes from the cosmetics contract-manufacturing business, while its pharmaceutical segment is anchored by a patch-form treatment for Alzheimer's disease.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$41.2M
- FY2024US$50.2M
- FY2025US$60.4M
Operating profit
- FY2023−US$16.4M
- FY2024−US$12.5M
- FY2025−US$8.7M
Net income
- FY2023−US$23.4M
- FY2024US$17.9K
- FY2025−US$25M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
The company has signed overseas licensing and supply agreements for its Alzheimer's patch with Menarini and Celltrion, both named in its filing.
Filings
All disclosures · English when translated- 최대주주변경을수반하는주식담보제공계약체결Ownership change · Sep 4
- 임원ㆍ주요주주특정증권등소유상황보고서Sep 4
- 주식등의대량보유상황보고서(일반)Sep 4
- 기타경영사항(자율공시) (최대주주 보유주식의 자발적 의무보유 시행)Sep 3
- [기재정정]최대주주변경Ownership change · Sep 3
- [기재정정]증권발행결과(자율공시) (제3자배정유상증자)Capital raise · Sep 3
- [기재정정]주요사항보고서(유상증자결정)Capital raise · Sep 3
- 주권매매거래정지해제 (상장유지 결정)Sep 2
- 기타시장안내 (기업심사위원회 심의·의결 결과 및 상장유지 결정 안내)Sep 2
- 최대주주변경을수반하는주식담보제공계약해제ㆍ취소등Ownership change · Sep 1
- [기재정정]최대주주변경Ownership change · Aug 31
- [기재정정]증권발행결과(자율공시)Aug 31
Price charts coming soon
Interactive price history isn't here yet. Would you use it?